ArticleDiabetes, obesity & metabolism2022

The time-varying cardiovascular benefits of glucagon-like peptide-1 receptor agonist therapy in patients with type 2 diabetes mellitus: Evidence from large multinational trials.

Salil V Deo et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.